F. Hoffmann-La Roche Ltd

Industry / private company

Location: Basel, Switzerland (CH) CH

ISNI: 0000000403741269

ROR: https://ror.org/00by1q217

Show on Map:


Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year




Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study (2023) Hurvitz SA, Bardia A, Quiroga V, Park YH, Blancas I, Alonso-Romero JL, Vasiliev A, et al. Journal article Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer (2023) Denkert C, Lambertini C, Fasching P, Pogue-Geile KL, Mano MS, Untch M, Wolmark N, et al. Journal article Tominersen in Adults with Manifest Huntington's Disease. (2023) McColgan P, Thobhani A, Boak L, Schobel SA, Nicotra A, Palermo G, Trundell D, et al. Journal article, Letter BISPECIFIC ANTIBODIES ENABLE SYNTHETIC AGONISTIC RECEPTOR T CELL THERAPY IN MELANOMA (2022) Benmebarek M, Maerkl F, Keyl J, Cadilha B, Geiger M, Karches C, Obeck H, et al. Conference contribution Modern Machine Learning Practices in Colorectal Surgery: A Scoping Review (2022) Taha-Mehlitz S, Däster S, Bach L, Ochs V, von Flüe M, Steinemann D, Taha A Journal article Effects of a Fully Humanized Type II Anti-CD20 Monoclonal Antibody on Peripheral and CNS B Cells in a Transgenic Mouse Model of Multiple Sclerosis (2022) Tacke S, Chunder R, Schropp V, Urich E, Kürten S Journal article Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial (2022) Sandborn WJ, Panés J, Danese S, Sharafali Z, Hassanali A, Jacob-Moffatt R, Eden C, et al. Journal article Deep Learning-based Propensity Scores for Confounding Control in Comparative Effectiveness Research: A Large-scale, Real-world Data Study (2021) Weberpals J, Becker T, Davies J, Schmich F, Ruettinger D, Theis FJ, Bauer-Mehren A Journal article A machine learning perspective on the emotional content of Parkinsonian speech (2021) Sechidis K, Fusaroli R, Orozco Arroyave JR, Wolf D, Zhang YP Journal article Treatment-related amenorrhea with T-DM1 plus pertuzumab (KP) is lower than with docetaxel/carboplatin/ trastuzumab/pertuzumab (TCHP) in the phase III neoadjuvant KRISTINE trial (2021) Hurvitz SA, Fresco R, Afenjar K, Stroyakovskiy D, Huang CS, Wildiers H, Jung KH, et al. Conference contribution
1 2 3 4